Don't count out a consumer spinoff, Pfizer executives say amid Q3 M&A grilling

31st October 2017 Uncategorised 0

Pfizer CEO Ian Read on Tuesday offered up prescription trends and launch details on the company’s key products, including the cancer therapies Ibrance and Xtandi. But it didn’t take long for analysts to turn the conversation back to their favorite Pfizer topic: M&A.

More: Don't count out a consumer spinoff, Pfizer executives say amid Q3 M&A grilling
Source: fierce